The most frequent reasons for withdrawal from randomized treatment were confusion and psychosis among those receiving dopamine agonists or MAO-B inhibitors and diarrhea among those receiving COMT inhibitors, which are all well-recognized AEs.21 Withdrawal from treatment was more common among older patients, suggesting a cautious approach to adjuvant therapy among that population. The gene discussed is COMT; the disease is psychotic disorder.